PFM Health Sciences’s Cytokinetics CYTK Stock Holding History

PFM Health Sciences’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,757,192	Closed	-$92.8M	–	91
2024 Q3	$92.8M	Hold	1,757,192	–	–	5.26%	3
2024 Q2	$95.2M	Hold	1,757,192	–	–	4.71%	2
2024 Q1	$123M	Hold	1,757,192	–	–	5.79%	2
2023 Q4	$147M	Sell	1,757,192 -642,353	-27%	-$23.3M	8.8%	2
2023 Q3	$70.7M	Hold	2,399,545	–	–	3.33%	4
2023 Q2	$78.3M	Hold	2,399,545	–	–	3.04%	4
2023 Q1	$84.4M	Hold	2,399,545	–	–	3.73%	4
2022 Q4	$110M	Sell	2,399,545 -65,471	-3%	-$2.82M	3.94%	2
2022 Q3	$119M	Hold	2,465,016	–	–	4.32%	1
2022 Q2	$96.8M	Hold	2,465,016	–	–	3.69%	2
2022 Q1	$90.7M	Hold	2,465,016	–	–	3.39%	6
2021 Q4	$112M	Sell	2,465,016 -694,685	-22%	-$26.8M	3.83%	5
2021 Q3	$113M	Buy	3,159,701 +1,472,689	+87%	+$43.4M	3.32%	5
2021 Q2	$33.4M	Buy	1,687,012 +150,639	+10%	+$3.54M	1.05%	37
2021 Q1	$35.7M	Buy	1,536,373 +565,222	+58%	+$12.1M	1.09%	33
2020 Q4	$20.2M	Buy	+971,151	New	+$17.7M	0.71%	54

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PFM Health Sciences's CYTK Position: Q4 2024 in Review

PFM Health Sciences sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 1,757,192 shares — an estimated $92.8M sold.

PFM Health Sciences first reported a position in CYTK in Q4 2020 and held it in 16 quarters. The position peaked at $147M in Q4 2023. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

PFM Health Sciences reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
PFM Health Sciences sold 1,757,192 Cytokinetics shares in Q4 2024, an estimated $92.8M.
PFM Health Sciences first reported a position in Cytokinetics in Q4 2020 and held it in 16 quarters.
PFM Health Sciences's Cytokinetics position peaked at $147M in Q4 2023.
346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.